Accueil / Communiqués / Pharm-Olam Unifies Data on Medidata Cloud, Eliminating Silos

Pharm-Olam Unifies Data on Medidata Cloud, Eliminating Silos

Wednesday, October 24th 2018 at 12:30pm UTC

CRO accelerates the delivery of life-changing therapies with a single
view of data for all clinical trial stakeholders

  • Pharm-Olam unifies operational systems supporting study execution
  • Global CRO optimizes clinical trial outcomes with Medidata’s
    artificial intelligence and machine learning
  • Customer adopts Medidata platform to power digital transformation
    for global sponsors

NEW YORK–(BUSINESS WIRE)– Today at NEXT
NYC
, Medidata (NASDAQ:MDSO) announced that Pharm-Olam
International
(Pharm-Olam) signed a new, five-year enterprise
agreement to unify operational systems supporting study execution on
Medidata Cloud, the Intelligence Platform for Life Sciences.

Pharm-Olam previously used multiple systems and vendors, which led to
duplicate data and silos requiring later integration. With Medidata, the
global contract research organization (CRO) will empower sponsors to
accelerate drug therapy time to market by providing a single, unified
view of clinical trials to all stakeholders.

Only Medidata offers a one platform approach, which:

  • Creates a single repository for all trial data
  • Streamlines clinical operations for study teams
  • Leverages artificial intelligence and real-world data analytics to
    identify anomalies to drive better data quality and accelerate
    clinical insights

“After an exhaustive search, we selected Medidata because only their
platform can unify all of our data and empower us to leapfrog the
competition,” said David L. Grange, CEO, Pharm-Olam. “Medidata drives
unmatched value for CROs across every part of clinical research. By
leveraging Medidata’s best-in-class technology, we will reduce costs and
provide superior solutions to our customers. It’s a win-win for us.”

Additional insights can be found in this video.

The Medidata Cloud provides clinical professionals – including, clinical
operations, data managers, and investigators – one platform for
end-to-end clinical research collaboration. Pharm-Olam will leverage a
full suite of solutions from Medidata Cloud to bring new efficiencies to
both operational processes and study execution, including:

  • Edge
    eTMF
    : unify content, data, and
    workflows with comprehensive real-time, end-to-end TMF management to
    share with other clinical partners
  • Rave
    EDC
    , RTSM,
    and eCOA/ePRO:
    leverage a single site interface to execute clinical trial data
    collection, randomize patients, manage drug supply and capture patient
    data directly from mobile devices
  • SHYFT
    QUANTUM RWE
    : analyze complex real-world data sets to validate
    trial design, improve site feasibility and conduct observational
    research at scale
  • Edge
    Site Grants
    : quickly and accurately develop grant proposals and
    efficiently contract budgets for investigative sites
  • Edge
    Site Payments:
    automatically trigger, calculate and disburse
    payments directly into a site’s bank account
  • Edge
    CTMS:
    optimize study operations, save costs and stay compliant
    when planning, conducting and monitoring studies
  • Edge
    Central Monitoring:
    improve clinical trial data quality and
    integrity by statistically cleaning data through machine learning

“We’re thrilled to expand our strategic partnership and help Pharm-Olam
drive digital transformation for their customers,” said Glen de Vries,
president and co-founder, Medidata. “For CROs and sponsors of all sizes,
our unified platform enables faster, better decision making that
accelerates research and the delivery of life-changing therapies to
patients.”

About Medidata

Medidata is leading the digital transformation of life sciences, with
the world’s most used platform for clinical development, commercial, and
real-world data. Powered by artificial intelligence and delivered by the
#1 ranked industry experts, the Intelligent Platform for Life Sciences
helps pharmaceutical, biotech, medical device companies, and academic
researchers accelerate value, minimize risk and optimize outcomes.
Medidata serves more than 1,000 customers and partners worldwide and
empowers more than 100,000 certified users everyday to create hope for
millions of patients. Discover the future of life sciences: www.mdsol.com

About Medidata NEXT

The Medidata
NEXT
global series is where science meets technology meets the
future, with interactive, hands-on learning opportunities to design,
execute, manage and monitor the next generation of clinical research.

About Pharm-Olam International

Pharm-Olam is Helping Create a Healthier World as a global, midsized CRO
that offers flexible, innovative and highly personalized clinical
solutions to pharmaceutical, biotechnology and life science companies.
Our team is well-known for producing quality results with reduced risk,
costs and timelines in challenging international trials. Learn more
about our full-service solutions, data protection services and expertise
in oncology, infectious diseases and vaccines, rare and orphan diseases,
pediatrics and general medicine at pharm-olam.com.

Contacts

Medidata Solutions:
Investors:
Betsy Frank, 917-522-4620
bfrank@mdsol.com
or
Media:
Erik
Snider, 646-362-2997
esnider@mdsol.com

Source: Medidata


Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …